zolpidem has been researched along with Adverse Drug Event in 16 studies
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.
zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sodium oxybate (SXB) is an approved drug for the treatment of excessive daytime sleepiness (EDS) and cataplexy in narcolepsy." | 5.14 | A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing. ( Feldman, N; George, CF; Grzeschik, SM; Inhaber, N; Lai, C; Steininger, TL; Zheng, Y, 2010) |
| "We estimated the occurrence of ED visits from zolpidem-attributed ADRs using nationally representative, public health surveillance of medication harms (National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project, 2010-2017)." | 3.96 | Changes in emergency department visits for zolpidem-attributed adverse drug reactions after FDA Drug Safety Communications. ( Budnitz, DS; Dal Pan, GJ; Geller, AI; Lovegrove, MC; Zhou, EH, 2020) |
| "Four randomized, double-blind, placebo-controlled, 4-period drug-drug interaction studies were conducted in healthy subjects to evaluate the pharmacokinetic and pharmacodynamic (PD) interactions between mirogabalin and commonly used central nervous system depressants." | 2.87 | Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug-Drug Interaction Studies in Healthy Subjects. ( Currie, A; Dishy, V; Dow, J; He, L; Ishizuka, H; Jansen, M; Mendell, J; Merante, D; Zahir, H, 2018) |
| " The overall incidence and nature of adverse events was comparable between the two groups." | 2.73 | Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. ( Roth, T; Soubrane, C; Walsh, JK, 2008) |
| "Stimulated reporting occurs when patients and healthcare professionals are influenced or "stimulated" by media publicity to report specific drug-related adverse reactions, significantly biasing pharmacovigilance analyses." | 1.46 | Spontaneous Adverse Event Reports Associated with Zolpidem in the United States 2003-2012. ( Fois, RA; Grunstein, RR; Hanrahan, JR; Hibbs, DE; Ho, SS; Marshall, NS; Saini, B; Wong, CK, 2017) |
| "The prevalence of adverse reactions to zolpidem was investigated in a subpopulation of participants in the Drug Event Monitoring project of the Japan Pharmaceutical Association." | 1.43 | Safety analysis of zolpidem in elderly subjects 80 years of age or older: adverse event monitoring in Japanese subjects. ( Hirota, S; Ishizuka, T; Kajiwara, A; Koda, H; Morita, K; Murase, M; Nakagawa, K; Oniki, K; Saruwatari, J; Yamamura, M, 2016) |
| "When the US FDA approves a new prescription drug there is still a great deal remaining to be learned about the safe and proper use of that product." | 1.42 | Methodological approaches to evaluate the impact of FDA drug safety communications. ( Avorn, J; Brownstein, JS; Campbell, EG; Dal Pan, GJ; Kesselheim, AS; Lappin, BM; Rausch, P; Schneeweiss, S; Schwartz, LM; Seeger, JD; Toomey, T; Woloshin, S; Zhou, EH, 2015) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 12 (75.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Geller, AI | 1 |
| Zhou, EH | 3 |
| Budnitz, DS | 1 |
| Lovegrove, MC | 1 |
| Dal Pan, GJ | 3 |
| Nowogrodzki, A | 1 |
| Jansen, M | 1 |
| Mendell, J | 1 |
| Currie, A | 1 |
| Dow, J | 1 |
| He, L | 1 |
| Merante, D | 1 |
| Dishy, V | 1 |
| Ishizuka, H | 1 |
| Zahir, H | 1 |
| Moore, TJ | 1 |
| Mattison, DR | 1 |
| Schifano, F | 1 |
| Chiappini, S | 1 |
| Corkery, JM | 1 |
| Guirguis, A | 1 |
| Aschenbrenner, DS | 1 |
| Kajiwara, A | 1 |
| Yamamura, M | 1 |
| Murase, M | 1 |
| Koda, H | 1 |
| Hirota, S | 1 |
| Ishizuka, T | 1 |
| Morita, K | 1 |
| Oniki, K | 1 |
| Saruwatari, J | 1 |
| Nakagawa, K | 1 |
| Kesselheim, AS | 2 |
| Campbell, EG | 2 |
| Schneeweiss, S | 1 |
| Rausch, P | 2 |
| Lappin, BM | 2 |
| Seeger, JD | 1 |
| Brownstein, JS | 1 |
| Woloshin, S | 1 |
| Schwartz, LM | 1 |
| Toomey, T | 1 |
| Avorn, J | 2 |
| Wong, CK | 1 |
| Marshall, NS | 1 |
| Grunstein, RR | 1 |
| Ho, SS | 1 |
| Fois, RA | 1 |
| Hibbs, DE | 1 |
| Hanrahan, JR | 1 |
| Saini, B | 1 |
| McGraw, SA | 1 |
| Dejene, SZ | 1 |
| George, CF | 1 |
| Feldman, N | 1 |
| Inhaber, N | 1 |
| Steininger, TL | 1 |
| Grzeschik, SM | 1 |
| Lai, C | 1 |
| Zheng, Y | 1 |
| Tsai, MY | 1 |
| Tsai, MH | 1 |
| Yang, SC | 1 |
| Tseng, YL | 1 |
| Chuang, YC | 1 |
| Walsh, JK | 1 |
| Soubrane, C | 1 |
| Roth, T | 1 |
3 trials available for zolpidem and Adverse Drug Event
| Article | Year |
|---|---|
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug-Drug Interaction Studies in Healthy Subjects.
Topics: Adolescent; Adult; Bridged Bicyclo Compounds; Drug Interactions; Drug-Related Side Effects and Adver | 2018 |
A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing.
Topics: Adjuvants, Anesthesia; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Comorbi | 2010 |
Efficacy and safety of zolpidem extended release in elderly primary insomnia patients.
Topics: Aged; Analysis of Variance; Delayed-Action Preparations; Double-Blind Method; Drug-Related Side Effe | 2008 |
13 other studies available for zolpidem and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Changes in emergency department visits for zolpidem-attributed adverse drug reactions after FDA Drug Safety Communications.
Topics: Drug-Related Side Effects and Adverse Reactions; Emergency Service, Hospital; Female; Hospitalizatio | 2020 |
Clinical research: Inequality in medicine.
Topics: Animals; Animals, Laboratory; Apolipoprotein E4; Biomedical Research; Drug-Related Side Effects and | 2017 |
Assessment of Patterns of Potentially Unsafe Use of Zolpidem.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Depression; Dose-Response Relationship, Drug; Drug-Relat | 2018 |
An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions.
Topics: Acetamides; Adolescent; Adult; Azabicyclo Compounds; Databases, Factual; Drug Misuse; Drug-Related S | 2019 |
Common Insomnia Drugs Receive Black Box Warning.
Topics: Acetamides; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Eszopiclone; Humans; Pyr | 2019 |
Safety analysis of zolpidem in elderly subjects 80 years of age or older: adverse event monitoring in Japanese subjects.
Topics: Aged, 80 and over; Aging; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; | 2016 |
Methodological approaches to evaluate the impact of FDA drug safety communications.
Topics: Communication; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Humans; Hypnotics and | 2015 |
Spontaneous Adverse Event Reports Associated with Zolpidem in the United States 2003-2012.
Topics: Adolescent; Adult; Aged; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypnotics | 2017 |
Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study.
Topics: Adult; Aged; Communication; Drug-Related Side Effects and Adverse Reactions; Eszopiclone; Female; Hu | 2017 |
Transient global amnesia-like episode due to mistaken intake of zolpidem: drug safety concern in the elderly.
Topics: Aged; Amnesia, Transient Global; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hy | 2009 |